
    
      A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to
      evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal
      antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in
      patients with active, moderate-to-severe, ulcerative colitis
    
  